COVID-19 treatment in patients with comorbidities: Awareness of drug-drug interactions.

Back, David; Marzolini, Catia; Hodge, Catherine; Marra, Fiona; Boyle, Alison; Gibbons, Sara; Burger, David; Khoo, Saye

Back, David; Marzolini, Catia; Hodge, Catherine; Marra, Fiona; Boyle, Alison; Gibbons, Sara; Burger, David; Khoo, Saye.

Back D; Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.
Marzolini C; Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.
Hodge C; Division of Infectious Diseases and Hospital Epidemiology, Departments of Medicine and Clinical Research, University Hospital of Basel, Basel, Switzerland.
Marra F; University of Basel, Basel, Switzerland.
Boyle A; Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.
Gibbons S; Department of Pharmacy, NHS Greater Glasgow and Clyde, Glasgow, UK.
Burger D; Department of Pharmacy, NHS Greater Glasgow and Clyde, Glasgow, UK.
Khoo S; Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.

Br J Clin Pharmacol ; 87(1): 212-213, 2021 01.

Article in English | MEDLINE | ID: covidwho-209857

Subject(s)

Antiviral Agents; COVID-19 Drug Treatment; Pharmaceutical Preparations; Comorbidity; Drug Interactions; Drug Repositioning; Humans; SARS-CoV-2

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Pharmaceutical Preparations / COVID-19 Drug Treatment Limits: Humans Language: English Journal: Br J Clin Pharmacol Year: 2021 Document Type: Article Affiliation country: Bcp.14358

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google